Ultragenyx Pharmaceutical Inc. shares plunged 30% as UX143 trial raises efficacy doubts. Click for more on RARE and my reaction to the results.
Ultragenyx: ‘Hold’ The Best Strategy As Stock Tanks On Bone Disease Study Miss
view original post
Ultragenyx Pharmaceutical Inc. shares plunged 30% as UX143 trial raises efficacy doubts. Click for more on RARE and my reaction to the results.